RoukenBio

RoukenBio CRO redefined. RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalised approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally. Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments. RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to GMP-ready potency assay creation. Working across inflammation, auto-immunity, immuno-oncology and oncology, their...

Bioassays,adcc,mabs,adcs,bi-specifics,biosimilars,immuno-oncology,method development,t cell activation,t cells,tumor microenvironment,tdcc,cell line development,checkpoint inhibitors,immunology,immunotherapeutics,antibodytherapeutics,immune cell engagers,cro,services,biologics,nk cells,macrophages,dendritic cells,drug development,car-t,drug discovery,cell therapy,and tregs

Roukenbio operates in the Biotechnology research industry.

Roukenbio's revenue is 11m - 100m

Roukenbio has 51 - 200 employees.